Autologous NK cells as consolidation therapy following stem cell transplantation in multiple myeloma
Open Access
- 28 January 2022
- journal article
- research article
- Published by Elsevier in Cell Reports Medicine
- Vol. 3 (2) , 100508
Abstract
No abstract availableKeywords
Funding Information
- Radiumhemmets Forskningsfonder (184083)
- Radiumhemmets Forskningsfonder (191063)
- Cancerfonden (CAN 2017/505)
- Karolinska Institutet (WO 2019/211310 A1)
- VINNOVA (2010-00501)
- Stockholms Läns Landsting
- Vetenskapsrådet (VR2015-02499)
- Stiftelsen för Strategisk Forskning (RIF14-0045)
This publication has 58 references indexed in Scilit:
- Highly activated and expanded natural killer cells for multiple myeloma immunotherapyHaematologica, 2012
- Adoptive Transfer of Autologous Natural Killer Cells Leads to High Levels of Circulating Natural Killer Cells but Does Not Mediate Tumor RegressionClinical Cancer Research, 2011
- Confinement of Activating Receptors at the Plasma Membrane Controls Natural Killer Cell ToleranceScience Signaling, 2011
- Anti-myeloma activity of endogenous and adoptively transferred activated natural killer cells in experimental multiple myeloma modelExperimental Hematology, 2007
- International Staging System for Multiple MyelomaJournal of Clinical Oncology, 2005
- Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancerBlood, 2005
- Effectiveness of Donor Natural Killer Cell Alloreactivity in Mismatched Hematopoietic TransplantsScience, 2002
- In search of the ‘missing self’: MHC molecules and NK cell recognitionImmunology Today, 1990
- Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic CancerNew England Journal of Medicine, 1985
- Host resistance directed selectively against H-2-deficient lymphoma variants. Analysis of the mechanism.Journal of Experimental Medicine, 1985